site stats

Gemcitabine induced hemolytic uremic syndrome

WebMay 24, 2024 · The drug-induced secondary TMA is caused by chemotherapeutic agents such as gemcitabine, mitomycin C, and cisplatin. 1 In our present case report, the female patient with history of malignancy was treated using gemcitabine, which is compatible with the secondary TMA. WebApr 6, 2024 · Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential …

Gemcitabine induced hemolytic uremic syndrome. - Europe PMC

Weburemic syndrome Introduction Hemolytic uremic syndrome (HUS) is a principal subtype of thrombotic microangiopathic (TMA) syndromes that are characterized by common clinical and pathological features. Clinical features include microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and target organ damage, i.e., acute kidney injury in HUS [1]. WebFeb 1, 2009 · Gemcitabine is used in a variety of advanced malignancies. Hemolytic uremic syndrome has been reported as a side effect. Methods we reviewed medical records of 29 patients with gemcitabine nephrotoxicity. Results The median cumulative dose of gemcitabine was 22 g/m2 (4 - 81) given over 7.5 months (2 - 34). the thing 1945 https://maureenmcquiggan.com

Elevated reticulocyte count – a clue to the diagnosis of …

WebZurück zum Zitat Lee HW, Chung MJ, Kang H, Choi H, Choi YJ, Lee KJ et al (2014) Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver 8(1):109–112 CrossRefPubMedPubMedCentral Lee HW, Chung MJ, Kang H, Choi H, Choi YJ, Lee KJ et al (2014) Gemcitabine-induced … WebFeb 26, 1999 · Gemcitabine-induced hemolytic uremic syndrome: a case report (letter). J Natl Cancer Inst 89 : 1895–1896. Article CAS Google Scholar WebOct 1, 2010 · A 63-year-old man with Stage IVa pancreas tail cancer was admitted for a distal pancreatectomy and splenectomy; adjuvant chemotherapy with gemcitabine was also administered. The chemotherapy was... set custom folder icons for flash drive

PubMed Central (PMC)

Category:Elevated reticulocyte count – a clue to the diagnosis of haemolytic ...

Tags:Gemcitabine induced hemolytic uremic syndrome

Gemcitabine induced hemolytic uremic syndrome

Thieme E-Journals - Zeitschrift für Gastroenterologie / Abstract

WebPubMed Central (PMC) WebMay 15, 2024 · Yamada Y, Suzuki K, Nobata H, et al. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud’s phenomenon, positive antinuclear antibodies and hypertensive emergency. Intern Med. 2014;53:445–8. Article PubMed Google Scholar Scully M, Goodship T.

Gemcitabine induced hemolytic uremic syndrome

Did you know?

WebDec 31, 2008 · Gemcitabine or 2′, 2′-difluorodeoxycytidine is a pyrimidine antimetabolite that was introduced in 1987, for treatment of solid tumors. The first case of gemcitabine-related hemolytic uremic syndrome (HUS) was reported in 1994 [], and since then there have been numerous other case reports describing this association.Gemcitabine is now … WebAug 6, 2016 · Hemolytic–uremic syndrome (HUS) is a rare side effect of gemcitabine, which is reported as having a high morbidity and mortality despite interventions with …

WebMar 7, 2024 · Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential … WebAug 1, 2014 · Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, …

WebDec 31, 2008 · Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, …

WebJan 4, 2024 · Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by over-activation and dysregulation of the alternative complement pathway. Its estimated prevalence is 1-2 per million.

WebNov 19, 2000 · Gemcitabine is a novel nucleoside analogue with activity against pancreatic adenocarcinoma and nonsmall cell lung carcinoma (NSCLC) as well as other solid … the thing 192WebJan 4, 2024 · 5.4 Hemolytic Uremic Syndrome. Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis, can occur with gemcitabine. In clinical trials, HUS occurred in 0.25% of 2429 patients. Most fatal cases of renal failure were due to HUS [see Adverse Reactions (6.1)]. set custom refresh rate windows 11WebDec 17, 1997 · Hemolytic uremic syndrome (HUS) is a rare side effect of chemotherapeutic agents reported in patients treated with cisplatin and bleomycin … set custom background in teamsWebNational Center for Biotechnology Information set custom refresh rate windows 10WebJul 21, 2024 · Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in patients with gemcitabine-induced TMA (G-TMA). setcustomvalidity is not workingWebNov 19, 2000 · Gemcitabine is a novel nucleoside analogue with activity against pancreatic adenocarcinoma and nonsmall cell lung carcinoma (NSCLC) as well as other solid tumors. 59 - 61 It recently has been observed that gemcitabine rarely may be associated with HUS. 62, 63 This review examines the incidence of HUS associated with gemcitabine in the … set custom ringtone in iphoneWebApr 6, 2024 · Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with … set custom text